Novel 8-(furan-2-yl)-3-benzyl thiazolo [5,4-e][1,2,4] triazolo [1,5-c] pyrimidine-2(3H)-thione as selective adenosine A2A receptor antagonist

Adenosine A2A receptor (A2AR) antagonists have emerged as potential drug candidates to alleviate progression and symptoms of Parkinson's disease (PD), and reduce the dopaminergic side effects. The synthesis of novel compound 8-(furan-2-yl)-3-benzyl thiazolo [5,4-e][1,2,4] triazolo [1,5-c] pyrimidine-2-(3H)-thione (BTTP) was carried out to evaluate the potential of BTTP as A2AR antagonist using SCH58261, a standard A2AR antagonist. The strong interaction of BTTP with A2AR (ΔG = −12.46 kcal/mol and Ki = 0.6 nM) in silico analysis was confirmed by radioligand receptor binding studies showing high affinity (Ki = 0.004 nM) and selectivity with A2AR (A2A/A1 = 1155-fold). The effect of CGS21680 (selective A2AR agonist) induced cAMP concentration (0.1 pmol/ml) in HEK293 cells was antagonized with BTTP (0.065 pmol/ml) and SCH58261 (0.075 pmol/ml). Furthermore, BTTP pre-treated (5, 10 and 20 mg/kg) haloperidol-induced mice demonstrated significant attenuation in catalepsy and akinesia. BTTP induced elevation in the striatal dopamine concentration (2.90 μM/mg of tissue) was comparable to SCH58261 (2.92 μM/mg of tissue) at the dose of 10 mg/kg. The results firmly articulate that BTTP possesses potential A2AR antagonist activity and can be further explored for the treatment of PD.